117 related articles for article (PubMed ID: 9191873)
1. Phase IB trial of picibanil (OK-432) as an immunomodulator in patients with resected high-risk melanoma.
Kirkwood JM; Wilson J; Whiteside TL; Donnelly S; Herberman RB
Cancer Immunol Immunother; 1997 May; 44(3):137-49. PubMed ID: 9191873
[TBL] [Abstract][Full Text] [Related]
2. Effect of streptococcal lyzate OK-432 on peripheral blood mononuclear cells in gastric cancer patients.
Nakayama F; Iwagaki H; Gouchi A; Hizuta A; Isozaki H; Takakura N; Tanaka N
J Med; 1998; 29(3-4):199-215. PubMed ID: 9865458
[TBL] [Abstract][Full Text] [Related]
3. Potential advantages in therapeutic index of OK-432 ointment to abdominal skin over systemic applied in a mouse model.
Matsuoka H; Yano K; Wasasugi H; Seo Y; Saito T; Tomoda H
Cancer Lett; 1996 Mar; 101(1):15-20. PubMed ID: 8625276
[TBL] [Abstract][Full Text] [Related]
4. Cytokine-inducing activity and antitumor effect of a liposome-incorporated interferon-gamma-inducing molecule derived from OK-432, a streptococcal preparation.
Okamoto M; Gohda H; Ohe G; Yoshida H; Matsuno T; Saito M; Sato M
J Immunother; 2000 Jan; 23(1):94-103. PubMed ID: 10687142
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of antitumor effect on mouse hepatocellular carcinoma by intratumoral injection of OK-432, a streptococcal preparation.
Homma S; Sagawa Y; Komita H; Koido S; Nagasaki E; Ryoma Y; Okamoto M
Cancer Immunol Immunother; 2007 Aug; 56(8):1265-74. PubMed ID: 17219148
[TBL] [Abstract][Full Text] [Related]
6. Locoregional immunotherapy of malignant ascites from gastric cancer using DTH-oriented doses of the streptococcal preparation OK-432: Treatment of Th1 dysfunction in the ascites microenvironment.
Yamaguchi Y; Ohshita A; Kawabuchi Y; Hihara J; Miyahara E; Noma K; Toge T
Int J Oncol; 2004 Apr; 24(4):959-66. PubMed ID: 15010836
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of natural killer cell activity in human immunodeficiency virus-infected subjects by in vitro treatment with biologic response modifier OK-432.
Huang XL; Fan Z; Murayama T; Rinaldo C
Clin Diagn Lab Immunol; 1995 Jan; 2(1):91-7. PubMed ID: 7719919
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of antitumor activity of OK-432 (picibanil) by Triton X-114 phase partitioning.
Hashimoto M; Takashige K; Furuyashiki M; Yoshidome K; Sano R; Kawamura Y; Ijichi S; Morioka H; Koide H; Oku N; Moriya Y; Kusumoto S; Suda Y
Int Immunopharmacol; 2008 Jan; 8(1):12-9. PubMed ID: 18068095
[TBL] [Abstract][Full Text] [Related]
9. [Immunopotentiation by OK-432 ointment to apply to the mouse abdominal skin].
Matsuoka H; Yano K; Baba H; Kounoe S; Seo Y; Saito T; Tomoda H; Wakasugi H
Gan To Kagaku Ryoho; 1995 Sep; 22(11):1644-6. PubMed ID: 7574783
[TBL] [Abstract][Full Text] [Related]
10. Inhalation therapy using a streptococcal preparation (OK-432) against bronchioloalveolar carcinoma of the lung.
Yano T; Ichinose Y; Yokoyama H; Fukuyama Y; Sugio K; Sugimachi K
Anticancer Res; 1999; 19(6C):5511-4. PubMed ID: 10697608
[TBL] [Abstract][Full Text] [Related]
11. TNF-alpha is secreted by monocytes in transit to become macrophages, but not by peripheral blood monocytes, following OK-432 (lyophilized S. pyogenes) stimulation.
Olsnes C; Stavang H; Olofsson J; Aarstad HJ
Scand J Immunol; 2007 Dec; 66(6):684-93. PubMed ID: 18021366
[TBL] [Abstract][Full Text] [Related]
12. Activation of human peripheral blood-derived monocytes by OK-432 (Streptococcus pyogenes): augmented cytotoxicity and secretion of TNF and synergy with rIFN-gamma.
Bonavida B; Jewett A
Cell Immunol; 1989 Oct; 123(2):373-83. PubMed ID: 2507170
[TBL] [Abstract][Full Text] [Related]
13. [Case of malignant melanoma of the external genitalia responding satisfactorily to a combination of local injection of OK-432 and chemotherapy].
Satoh S; Suzuki A; Okamura H; Nishimura T
Gan To Kagaku Ryoho; 1982 Jan; 9(1):140-5. PubMed ID: 6820877
[TBL] [Abstract][Full Text] [Related]
14. [A double blind study of the evaluation of the optimal dose and its frequency in oral administration of OK-432 (Picibanil) by immunological parameters (the 1st report)].
Shiraishi T; Nio Y; Imai S; Tsubono M; Morimoto H; Tseng CC; Tobe T; Tanaka T; Kitamura O; Sakanashi S
Nihon Gan Chiryo Gakkai Shi; 1990 Apr; 25(4):799-811. PubMed ID: 2196311
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy for renal cell carcinoma using IFN-gamma and OK-432: in vitro study.
Muraki J
Keio J Med; 1990 Mar; 39(1):21-5. PubMed ID: 2113148
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral injection of a streptococcal preparation, OK-432, before surgery for gastric cancer. A randomized trial. Cooperative Study Group of Preoperative Intratumoral Immunotherapy for Cancer.
Tanaka N; Gouchi A; Ohara T; Mannami T; Konaga E; Fuchimoto S; Okamura S; Sato K; Orita K
Cancer; 1994 Dec; 74(12):3097-103. PubMed ID: 7982173
[TBL] [Abstract][Full Text] [Related]
17. Generation of activated killer-like cells by OK-432-mediated production of interleukin 1, interleukin 2, and interferon-gamma in vitro.
Ujiie T
Jpn J Exp Med; 1987 Dec; 57(6):333-8. PubMed ID: 3131563
[TBL] [Abstract][Full Text] [Related]
18. Cytokine-mediated antitumor effect of OK-432 on urinary bladder tumor cells in vitro.
Sakano S; Shimabukuro T; Ohmoto Y; Naito K
Urol Res; 1997; 25(4):239-45. PubMed ID: 9286031
[TBL] [Abstract][Full Text] [Related]
19. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma.
Alatrash G; Hutson TE; Molto L; Richmond A; Nemec C; Mekhail T; Elson P; Tannenbaum C; Olencki T; Finke J; Bukowski RM
J Clin Oncol; 2004 Jul; 22(14):2891-900. PubMed ID: 15254058
[TBL] [Abstract][Full Text] [Related]
20. Production of tumor necrosis factor (TNF) by monocytes from cancer patients and healthy subjects induced by OK-432 in vitro, and its augmentation by human interferon gamma.
Sekimoto M; Kokunai I; Shimano T; Kobayashi T; Takeda T; Haruna N; Yamamoto A; Mori T
J Clin Lab Immunol; 1988 Nov; 27(3):115-20. PubMed ID: 3150012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
